Jun-Il Yoo1, Yong-Chan Ha2, Miji Kim3, Sung-Hyo Seo4,5, Mi-Ji Kim5,6, Gyeong-Ye Lee5, Young-Mi Seo5, Changsu Sung5, Ki-Soo Park7,8. 1. Department of Orthopaedic Surgery, Gyeongsang National University Hospital, Jinju, Korea. 2. Department of Orthopaedic Surgery, Chung-Ang University College of Medicine, Seoul, Korea. 3. College of Medicine/East-West Medical Research Institute, Kyung Hee University, Seoul, Republic of Korea. 4. Department of Information & Statistics, College of Natural Science, Gyeongsang National University, Jinju, Republic of Korea. 5. Center for Farmer's Safety and Health, Gyeongsang National University Hospital, Jinju, Republic of Korea. 6. Department of Preventive Medicine, College of Medicine and Institute of Health Science, Gyeongsang National University, Jinju-daero, 816 Beon-gil 15, Jinju, 52727, Republic of Korea. 7. Center for Farmer's Safety and Health, Gyeongsang National University Hospital, Jinju, Republic of Korea. parkks@gnu.ac.kr. 8. Department of Preventive Medicine, College of Medicine and Institute of Health Science, Gyeongsang National University, Jinju-daero, 816 Beon-gil 15, Jinju, 52727, Republic of Korea. parkks@gnu.ac.kr.
Abstract
PURPOSE: The purpose of this paper was to translate and validate into the Korea language and setting the Sarcopenia Quality of Life (SarQoL®) questionnaire. METHODS: The participants consisted of 450 individuals in Namgaram-2 cohort who were followed up in 2019-2020. The study participants were divided into four groups: (1) SARC-F < 4, (2) SARC-F ≥ 4 and robust grip strength, (3) SARC-F ≥ 4, low grip strength, robust muscle mass, (4) SARC-F ≥ 4, low grip strength, and low muscle mass. To assess construct validity, population with sarcopenia-associated symptoms (SARC-F ≥ 4) apart from the Korean SarQoL (SarQoL-K®) completed the Korean versions of two generic questionnaires, the Short Form-36 and the EuroQoL 5-dimension. To validate the Korean SarQoL®, we assessed its validity (discriminative power, construct validity), reliability (internal consistency, test-retest reliability), and floor/ceiling effects. RESULTS: The SarQoL-K® questionnaire was translated without major difficulties. The mean SarQoL-K scores were 72.9 (95%, CI; 71.2-74.6) in SARC-F < 4, 54.6 (95%, CI; 50.7-58.3) in SARC-F ≥ 4 and robust grip strength, 47.0 (95%, CI; 43.8-50.1) in SARC-F ≥ 4, low grip strength, robust muscle mass, 46.6 (95%, CI; 43.0-50.1) in SARC-F ≥ 4, low grip strength, and low muscle mass. The results indicated good discriminative power across each four groups (p < 0.001), high internal consistency (Cronbach's alpha of 0.866), and excellent test-retest reliability (ICC = 0.977, 95% CI 0.975-0.979). No floor- or ceiling-effects were observed. CONCLUSIONS: This is the first study to confirm the reliability and validity of the Korean version of the SarQoL®. We demonstrated that the population with sarcopenia-associated symptoms (determined using the SARC-F questionnaire) has a lower quality of life.
PURPOSE: The purpose of this paper was to translate and validate into the Korea language and setting the Sarcopenia Quality of Life (SarQoL®) questionnaire. METHODS: The participants consisted of 450 individuals in Namgaram-2 cohort who were followed up in 2019-2020. The study participants were divided into four groups: (1) SARC-F < 4, (2) SARC-F ≥ 4 and robust grip strength, (3) SARC-F ≥ 4, low grip strength, robust muscle mass, (4) SARC-F ≥ 4, low grip strength, and low muscle mass. To assess construct validity, population with sarcopenia-associated symptoms (SARC-F ≥ 4) apart from the Korean SarQoL (SarQoL-K®) completed the Korean versions of two generic questionnaires, the Short Form-36 and the EuroQoL 5-dimension. To validate the Korean SarQoL®, we assessed its validity (discriminative power, construct validity), reliability (internal consistency, test-retest reliability), and floor/ceiling effects. RESULTS: The SarQoL-K® questionnaire was translated without major difficulties. The mean SarQoL-K scores were 72.9 (95%, CI; 71.2-74.6) in SARC-F < 4, 54.6 (95%, CI; 50.7-58.3) in SARC-F ≥ 4 and robust grip strength, 47.0 (95%, CI; 43.8-50.1) in SARC-F ≥ 4, low grip strength, robust muscle mass, 46.6 (95%, CI; 43.0-50.1) in SARC-F ≥ 4, low grip strength, and low muscle mass. The results indicated good discriminative power across each four groups (p < 0.001), high internal consistency (Cronbach's alpha of 0.866), and excellent test-retest reliability (ICC = 0.977, 95% CI 0.975-0.979). No floor- or ceiling-effects were observed. CONCLUSIONS: This is the first study to confirm the reliability and validity of the Korean version of the SarQoL®. We demonstrated that the population with sarcopenia-associated symptoms (determined using the SARC-F questionnaire) has a lower quality of life.
Entities:
Keywords:
Cross cultural adaptation; Korea; Quality of life; Sarcopenia
Authors: Charlotte Beaudart; Mark Edwards; Charlotte Moss; Jean-Yves Reginster; Rebecca Moon; Camille Parsons; Christophe Demoulin; René Rizzoli; Emmanuel Biver; Elaine Dennison; Olivier Bruyere; Cyrus Cooper Journal: Age Ageing Date: 2017-03-01 Impact factor: 10.668
Authors: María Visitación Martínez-Fernández; Irene Sandoval-Hernández; Alejandro Galán-Mercant; Manuel Gonzalez-Sanchez; Jesús Martínez-Cal; Guadalupe Molina-Torres Journal: Int J Environ Res Public Health Date: 2022-04-10 Impact factor: 4.614